Full-Time

Regional Account Manager

Rare Disease

Posted on 5/8/2026

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

Compensation Overview

$185.5k - $202k/yr

+ Annual Bonus Program

Pennsylvania, USA + 7 more

More locations: Delaware, USA | Jackson Township, NJ, USA | Tennessee, USA | Virginia, USA | Kentucky, USA | New York, NY, USA | Maryland, USA

In Person

Category
Sales & Account Management (1)
Required Skills
Power BI
Requirements
  • Bachelor’s degree in science or business required
  • Minimum of 5 years of rare disease experience or experience selling in complex disease states preferred
  • Demonstrated experience and success in patient identification, disease education, or complex diagnostic markets
  • Proven ability to operate effectively in long-cycle sales environments
  • Strong analytical skills with the ability to translate data into actionable territory strategies
  • Demonstrated ability to influence multiple stakeholders without direct authority
  • Strong verbal, written, presentation, and interpersonal communication skills
  • Ability to work autonomously while maintaining strong cross-functional collaboration
  • Residence within close proximity to assigned geography
  • Commitment to continuous learning and professional development
Responsibilities
  • Identify rare disease patients through engagement with healthcare providers, including but not limited to internal medicine and family practice physicians, general pediatrics, rheumatology, physical therapy, pain management, and other non-traditional specialties
  • Identify and address diagnostic gaps within targeted accounts that may delay or prevent accurate diagnosis
  • Map, influence, and support local diagnostic and referral pathways to reduce time from disease suspicion to confirmed diagnosis
  • Support appropriate use of diagnostic tools and specialist referrals, including utilization of approved HCP identification tools
  • Serve as a field integrator to help ensure potential patients are identified throughout the diagnostic journey
  • Develop and execute a business plan focused on patient identification and diagnostic activation
  • Utilize claims data, internal analytics, Power BI mapping, and other approved data sources to identify high-probability patient opportunities
  • Continuously refine targeting and territory strategy based on real-world outcomes, field insights, and performance metrics
  • Analyze local and regional trends to inform short- and long-term business planning
  • Partner closely with Regional Business Managers and appropriate cross-functional partners to ensure coordinated, compliant patient identification efforts
  • Execute compliant transitions of qualified patient opportunities to RBMs for treatment initiation and account execution
  • Communicate all disease, diagnostic, and product-related information in a truthful, non-misleading manner consistent with company policies and all applicable laws and regulations
  • Utilize only on-label, approved materials and seek guidance from management, Compliance, or Legal when uncertainty exists
  • Adhere strictly to all regulatory, compliance, and company policies, including appropriate handling of confidential patient information
Desired Qualifications
  • Experience in rare disease or other highly specialized therapeutic areas
  • Demonstrated understanding of referral networks
  • Strong business planning and strategic thinking capabilities
  • Strong business development skills
  • Experience with regional sales or account management in rare disease preferred
  • Proficiency with data visualization and analytics platforms beyond basic}}

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Kyowa Kirin who can refer or advise you

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.

INACTIVE